 |
 |
Statisticians routinely make decisions about success or failure within Phase 2 trials. A more recent concept has been to make inferences about future observations, conditional on Phase 2 results to inform discussions about the potential success of Phase 3 designs.
Statisticians in the Pharmaceutical Industry (PSI) are hosting a 1-day scientific meeting which provides an opportunity to learn how the industry is working towards an ultimate goal of reducing late phase failures and includes specific case studies that illustrate the analytical challenges. Presentations will be from statisticians across the industry working in this area.
Speakers include Graeme Archer (GSK), Bjoern Bornkamp (Novartis), Andy Grieve (Aptiv Solutions), Ian Hirsch and Sally Hollis (AstraZeneca), Simon Kirby (Pfizer), James Matcham (Amgen), Lucy Rowell (Roche) and Trevor Smart (Eli Lilly). Further updates and exact timings to the programme will be forthcoming.
The meeting will start at 9am and will be held at the GSK site in Stevenage, finishing at 5pm. The fee is £100 for PSI members and £140 for non-members before the 13th March or £140 for PSI members and £200 for non-members thereafter. A reduced fee of £40 (or £70 after 13th March) is available to academics.
The full agenda can be found at http://www.psiweb.org/docs/psiflyer_predictive_inference.doc
Registrations can be made via the PSI web site at http://www.psiweb.org.
SIGNOFF allstat
to [log in to unmask], leaving the subject line blank.